Assessment of Takayasu arteritis in routine practice with PETVAS, an 18F-FDG PET quantitative scoring tool.

Kaymaz Tahra S., Özgüven S., Ünal A. U., Alibaz Öner F., Öneş T., Erdil T. Y., ...Daha Fazla

Turkish journal of medical sciences, cilt.52, ss.313-322, 2022 (SCI-Expanded) identifier identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 52
  • Basım Tarihi: 2022
  • Doi Numarası: 10.3906/sag-2106-129
  • Dergi Adı: Turkish journal of medical sciences
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.313-322
  • Anahtar Kelimeler: Large-vessel vasculitis, imaging, positron emission tomography, fluorodeoxyglucose, Takayasu arteritis, LARGE-VESSEL VASCULITIS, POSITRON-EMISSION-TOMOGRAPHY, GIANT-CELL ARTERITIS, DISEASE-ACTIVITY, F-18-FDG PET/CT, WALL INFLAMMATION, DIAGNOSIS, MANAGEMENT, PATIENT, TIME
  • Marmara Üniversitesi Adresli: Evet

Özet

Background/aim: The aim of this study was to evaluate the value of the PET vascular activity score (PETVAS) during the follow-up of patients with Takayasu arteritis. Materials and methods: Takayasu arteritis patients who underwent 18F-Fluorodeoxyglucose (FDG) PET imaging were evaluated retrospectively. In 8 patients both 1 and 2-h imagings were also performed prospectively. For PETVAS, 9 arterial areas were scored between 0-3 according to the FDG uptake. Results: Forty-six images of 34 patients were evaluated. PETVAS was higher in patients with clinically active disease (p = 0.03) and in the C-reactive protein (CRP) elevated group among clinically inactive patients (p = 0.0015). PETVAS correlated with CRP (p = 0.003, r = 0.53) and erythrocyte sedimentation rate (p = 0.005, r = 0.41), whereas age, disease duration, immunosuppressive, and glucocorticoid (GC) treatments were not associated with PETVAS. First vs. 2nd-h PETVAS was similar in patients who had both 1st and 2nd h PET scans (p = 0.67). Conclusion: We observed higher PETVAS in patients with active disease and elevated acute phase reactants. Although scores in our study (performed at one-h) were lower compared to the original PETVAS study performed at two h, PETVAS seems to be a reliable tool to quantify FDG PET scores in routine practice.